<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150059</url>
  </required_header>
  <id_info>
    <org_study_id>CASM981CPH01</org_study_id>
    <nct_id>NCT00150059</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of pimecrolimus cream 1% in its registered indication
      (treatment of patients &gt; 3 months of age with mild to moderate atopic dermatitis)

      This study is not enrolling patients in the United States.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Global Assessment (IGA) score for the whole body and for the face only.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pruritus (itch) severity assessments, and patient's self-assessment of disease control at the start of study and on day 7, 30 and 90 after treatment initiation.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by adverse events.</measure>
  </primary_outcome>
  <condition>Atopic Dermatitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimecrolimus Cream 1%</intervention_name>
    <other_name>Elidel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The patient population must consist of male or female outpatients, age ≥3 months old with
        mild to moderate atopic dermatitis (IGA ≥ 1). Exclusion criteria are pregnancy, having
        active viral infections at the site(s) of treatment, presenting with systemic malignancy or
        active lymphoproliferative diseases/disorders, receiving phototherapy or immunosuppressive
        therapy, having used tacrolimus ointment and known allergy or hypersensitivity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Healthcare Philippines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>This study is not being conducted in the United States</name>
      <address>
        <city>Investigative Site</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>February 14, 2008</last_update_submitted>
  <last_update_submitted_qc>February 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>atopic dermatitis, eczema, mild to moderate, children, IGA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

